Myeloma Paper of the Day, May 18th, suggested by Robert Orlowski
Robert Orlowski shared on X:
“Myeloma Paper of the Day: Myeloma patients with long remission post-ASCT (PFS ≥8 years) tend to be younger, have good risk cytogenetics, baseline <50% BM PCs and R-ISS stage I, and receive maintenance.”
Source: Robert Orlowski/X
Authors: Oren Pasvolsky, Zhongya Wang, Denái R. Milton, Mark R. Tanner, Qaiser Bashir, Samer Srour, Neeraj Saini, Paul Lin, Jeremy Ramdial, Yago Nieto, Guilin Tang, Partow Kebriaei, Yosra Aljawai, Hina N. Khan, Hans C. Lee, Christine Ye, Krina K. Patel, Sheeba K. Thomas, Robert Z. Orlowski, Elizabeth J. Shpall, Richard E. Champlin, and Muzaffar H. Qazilbash.
Other insights by Robert Orlowski on OncoDaily.
Robert Orlowski holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine.
Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.
